Psilocybin
What you gain
Short course with early process-measure signals.
What it asks of you
Self-pay and no stuckness indication.
Comparison guide
Psilocybin or Spravato for Feeling Stuck
Spravato’s evidence and coverage path are for depression. Psilocybin has early rumination and flexibility signals — still not a “stuck” indication.
Answers at a glance
Comprehensive comparison
Psilocybin
Process measures usually checked at 1–6 weeks.12
Spravato
Antidepressant effects can appear within a day under the depression label.34
Psilocybin
Early signals reported across weeks — not a stuckness timeline.
Spravato
Built for ongoing clinic visits when depression is treated.
Psilocybin
Nothing daily to stop.
Spravato
Depression symptoms may return when visits stop.
Psilocybin
1–2 supported dosing days plus integration.12
Spravato
Twice weekly at first, then less often — a depression schedule, not a stuckness program.3
Psilocybin
OR/CO guided courses often about $850–$4,500+.5
Spravato
Clinic visit pricing; often lower out-of-pocket when insurance covers depression care.
Psilocybin
Almost never.
Spravato
Sometimes for depression — not for nonspecific stuckness.3
Psilocybin
Early signals from depression studies measuring flexibility and rumination.12
Spravato
Strong for depression; not proven for generic life stuckness.34
References & sources
- 1Sloshower et al. (2024). Psilocybin and psychological flexibility. View study →
- 2Barba et al. (2022). Psilocybin and rumination / thought suppression. View study →
- 3FDA. SPRAVATO labeled uses (depression). View study →
- 4Nikolin et al. (2023). Review of esketamine antidepressant effects. View study →
- 5Oregon Health Authority. Accessing psilocybin services. View study →
Typical US ranges and outcomes; your care depends on screening and clinical need. Not medical advice.
Considerations
Every path has a trade
Spravato
What you gain
Coverage path when depression is diagnosed.
What it asks of you
Ongoing visits and no stuckness evidence.